Disease modifying agent related skin reactions in multiple sclerosis: Prevention, assessment, and management

Elliot Frohman, K. Brannon, Sherry Alexander, D. Sims, J. T. Phillips, S. O'Leary, K. Hawker, M. K. Racke

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Background: The objective for this article is to highlight some of the adverse skin manifestations associated with injectable disease modifying therapy for multiple sclerosis (MS). Early identification and intervention can often lead to minimal consequences and prolonged patient tolerance and compliance with these agents. At the University of Texas Southwestern Medical Center at Dallas and Texas Neurology in Dallas we actively follow approximately 5000 MS patients. The majority of our patients with relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS) are treated with one of the currently available disease modifying agents (DMAs). Our experience with these patients, and the challenges they face in continuing long-term treatment, constitutes the basis of our proposed treatment strategies. Conclusion: Skin reactions in response to injectable DMA therapy in MS are generally mild. However, some reactions can evolve into potentially serious lesions culminating in infection, necrosis, and in some circumstances requiring surgical repair.

Original languageEnglish (US)
Pages (from-to)302-307
Number of pages6
JournalMultiple Sclerosis
Volume10
Issue number3
DOIs
StatePublished - Jun 2004

Fingerprint

Multiple Sclerosis
Skin
Chronic Progressive Multiple Sclerosis
Skin Manifestations
Relapsing-Remitting Multiple Sclerosis
Injections
Therapeutics
Patient Compliance
Neurology
Necrosis
Infection

Keywords

  • Abscess
  • Erythema
  • Glatiramer acetate
  • Interferon beta
  • Necrosis

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Disease modifying agent related skin reactions in multiple sclerosis : Prevention, assessment, and management. / Frohman, Elliot; Brannon, K.; Alexander, Sherry; Sims, D.; Phillips, J. T.; O'Leary, S.; Hawker, K.; Racke, M. K.

In: Multiple Sclerosis, Vol. 10, No. 3, 06.2004, p. 302-307.

Research output: Contribution to journalArticle

Frohman, E, Brannon, K, Alexander, S, Sims, D, Phillips, JT, O'Leary, S, Hawker, K & Racke, MK 2004, 'Disease modifying agent related skin reactions in multiple sclerosis: Prevention, assessment, and management', Multiple Sclerosis, vol. 10, no. 3, pp. 302-307. https://doi.org/10.1191/1352458504ms1002oa
Frohman, Elliot ; Brannon, K. ; Alexander, Sherry ; Sims, D. ; Phillips, J. T. ; O'Leary, S. ; Hawker, K. ; Racke, M. K. / Disease modifying agent related skin reactions in multiple sclerosis : Prevention, assessment, and management. In: Multiple Sclerosis. 2004 ; Vol. 10, No. 3. pp. 302-307.
@article{8f0bba99287341d08415f8e672f400f4,
title = "Disease modifying agent related skin reactions in multiple sclerosis: Prevention, assessment, and management",
abstract = "Background: The objective for this article is to highlight some of the adverse skin manifestations associated with injectable disease modifying therapy for multiple sclerosis (MS). Early identification and intervention can often lead to minimal consequences and prolonged patient tolerance and compliance with these agents. At the University of Texas Southwestern Medical Center at Dallas and Texas Neurology in Dallas we actively follow approximately 5000 MS patients. The majority of our patients with relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS) are treated with one of the currently available disease modifying agents (DMAs). Our experience with these patients, and the challenges they face in continuing long-term treatment, constitutes the basis of our proposed treatment strategies. Conclusion: Skin reactions in response to injectable DMA therapy in MS are generally mild. However, some reactions can evolve into potentially serious lesions culminating in infection, necrosis, and in some circumstances requiring surgical repair.",
keywords = "Abscess, Erythema, Glatiramer acetate, Interferon beta, Necrosis",
author = "Elliot Frohman and K. Brannon and Sherry Alexander and D. Sims and Phillips, {J. T.} and S. O'Leary and K. Hawker and Racke, {M. K.}",
year = "2004",
month = "6",
doi = "10.1191/1352458504ms1002oa",
language = "English (US)",
volume = "10",
pages = "302--307",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Disease modifying agent related skin reactions in multiple sclerosis

T2 - Prevention, assessment, and management

AU - Frohman, Elliot

AU - Brannon, K.

AU - Alexander, Sherry

AU - Sims, D.

AU - Phillips, J. T.

AU - O'Leary, S.

AU - Hawker, K.

AU - Racke, M. K.

PY - 2004/6

Y1 - 2004/6

N2 - Background: The objective for this article is to highlight some of the adverse skin manifestations associated with injectable disease modifying therapy for multiple sclerosis (MS). Early identification and intervention can often lead to minimal consequences and prolonged patient tolerance and compliance with these agents. At the University of Texas Southwestern Medical Center at Dallas and Texas Neurology in Dallas we actively follow approximately 5000 MS patients. The majority of our patients with relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS) are treated with one of the currently available disease modifying agents (DMAs). Our experience with these patients, and the challenges they face in continuing long-term treatment, constitutes the basis of our proposed treatment strategies. Conclusion: Skin reactions in response to injectable DMA therapy in MS are generally mild. However, some reactions can evolve into potentially serious lesions culminating in infection, necrosis, and in some circumstances requiring surgical repair.

AB - Background: The objective for this article is to highlight some of the adverse skin manifestations associated with injectable disease modifying therapy for multiple sclerosis (MS). Early identification and intervention can often lead to minimal consequences and prolonged patient tolerance and compliance with these agents. At the University of Texas Southwestern Medical Center at Dallas and Texas Neurology in Dallas we actively follow approximately 5000 MS patients. The majority of our patients with relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS) are treated with one of the currently available disease modifying agents (DMAs). Our experience with these patients, and the challenges they face in continuing long-term treatment, constitutes the basis of our proposed treatment strategies. Conclusion: Skin reactions in response to injectable DMA therapy in MS are generally mild. However, some reactions can evolve into potentially serious lesions culminating in infection, necrosis, and in some circumstances requiring surgical repair.

KW - Abscess

KW - Erythema

KW - Glatiramer acetate

KW - Interferon beta

KW - Necrosis

UR - http://www.scopus.com/inward/record.url?scp=3042694842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042694842&partnerID=8YFLogxK

U2 - 10.1191/1352458504ms1002oa

DO - 10.1191/1352458504ms1002oa

M3 - Article

C2 - 15222696

AN - SCOPUS:3042694842

VL - 10

SP - 302

EP - 307

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 3

ER -